Skeletal muscle has the innate ability to robustly regenerate in a highly orchestrated fashion that is initiated by satellite cells, the resident stem cell population. These cells are defined by their uniform expression of the transcription factor, PAX7, which plays a key role in myogenesis through specification and maintenance of satellite cells, as well as regulation of myogenic differentiation. In conditions of skeletal muscle wasting such as cachexia, sarcopenia, and muscular dystrophies, the deterioration of muscle overwhelms the regenerative capabilities of satellite cells, which are believed to undergo early senescence due to exhaustive proliferation. There is significant potential for harnessing satellite cells for gene and cell therapies for such diseases;​ however, satellite cell specification and regulation is still poorly understood.

The CRISPR/Cas9 system has been established as a multifaceted tool that can be used as a platform for a variety of applications, including sequence-specific genome and epigenome editing for cell differentiation and treatment of genetic diseases. The objective of my research proposal was to use CRISPR/Cas9-based genome engineering technologies toward applications for skeletal muscle regeneration. First, I used a CRISPR/Cas9-based transcriptional activator to direct differentiation of human pluripotent stem cells into functional skeletal muscle progenitor cells. Next, I conducted a high-throughput CRISPR activation screen to identify novel upstream regulators of myogenic progenitor cell differentiation. Lastly, I demonstrated that satellite cells can be targeted in vivo with AAV and subsequently gene-edited to correct the dystrophin reading frame in a mouse model for Duchenne muscular dystrophy. Together, this work provides novel contributions to the field of satellite cell biology and highlights the utility of CRISPR/Cas9 genome engineering in stem cells for skeletal muscle regeneration.